Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of cannabinoids in schizophrenia.
Recent Pat CNS Drug Discov. 2014 Apr; 9(1):13-25.RP

Abstract

Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during pathophysiological conditions. In the brain, activation of this system impacts the release of numerous neurotransmitters in various systems and cytokines from glial cells. Hence, the endocannabinoid system is strongly involved in neuropsychiatric disorders, such as schizophrenia. Therefore, adolescence use of Cannabis may alter the endocannabinoid signalling and pose a potential environmental risk to develop psychosis. Consistently, preclinical and clinical studies have found a dysregulation in the endocannabinoid system such as changed expression of CB1 and CB2 receptors or altered levels of AEA and 2-AG . Thus, due to the partial efficacy of actual antipsychotics, compounds which modulate this system may provide a novel therapeutic target for the treatment of schizophrenia. The present article reviews current available knowledge on herbal, synthetic and endogenous cannabinoids with respect to the modulation of schizophrenic symptomatology. Furthermore, this review will be highlighting the therapeutic potential of cannabinoid-related compounds and presenting some promising patents targeting potential treatment options for schizophrenia.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableCEITEC (Central European Institute of Technology) Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic. vincenzomicale@inwind.it.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24605939

Citation

Kucerova, Jana, et al. "Therapeutic Potential of Cannabinoids in Schizophrenia." Recent Patents On CNS Drug Discovery, vol. 9, no. 1, 2014, pp. 13-25.
Kucerova J, Tabiova K, Drago F, et al. Therapeutic potential of cannabinoids in schizophrenia. Recent Pat CNS Drug Discov. 2014;9(1):13-25.
Kucerova, J., Tabiova, K., Drago, F., & Micale, V. (2014). Therapeutic potential of cannabinoids in schizophrenia. Recent Patents On CNS Drug Discovery, 9(1), 13-25.
Kucerova J, et al. Therapeutic Potential of Cannabinoids in Schizophrenia. Recent Pat CNS Drug Discov. 2014;9(1):13-25. PubMed PMID: 24605939.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic potential of cannabinoids in schizophrenia. AU - Kucerova,Jana, AU - Tabiova,Katarina, AU - Drago,Filippo, AU - Micale,Vincenzo, PY - 2014/02/04/received PY - 2014/03/03/revised PY - 2014/03/06/accepted PY - 2014/3/11/entrez PY - 2014/3/13/pubmed PY - 2014/12/23/medline SP - 13 EP - 25 JF - Recent patents on CNS drug discovery JO - Recent Pat CNS Drug Discov VL - 9 IS - 1 N2 - Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during pathophysiological conditions. In the brain, activation of this system impacts the release of numerous neurotransmitters in various systems and cytokines from glial cells. Hence, the endocannabinoid system is strongly involved in neuropsychiatric disorders, such as schizophrenia. Therefore, adolescence use of Cannabis may alter the endocannabinoid signalling and pose a potential environmental risk to develop psychosis. Consistently, preclinical and clinical studies have found a dysregulation in the endocannabinoid system such as changed expression of CB1 and CB2 receptors or altered levels of AEA and 2-AG . Thus, due to the partial efficacy of actual antipsychotics, compounds which modulate this system may provide a novel therapeutic target for the treatment of schizophrenia. The present article reviews current available knowledge on herbal, synthetic and endogenous cannabinoids with respect to the modulation of schizophrenic symptomatology. Furthermore, this review will be highlighting the therapeutic potential of cannabinoid-related compounds and presenting some promising patents targeting potential treatment options for schizophrenia. SN - 2212-3954 UR - https://www.unboundmedicine.com/medline/citation/24605939/Therapeutic_potential_of_cannabinoids_in_schizophrenia_ L2 - http://www.eurekaselect.com/120809/article DB - PRIME DP - Unbound Medicine ER -